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Abstract
Background: Adult granulosa cell tumors of the ovary (GCTs) are sex cord stromal tumors of
unpredictable behaviour. Up to now, the prediction of the relapsing/malignant potential remains
difficult. CD56 (NCAM) in GCTs was previously described in only two studies. However, the
expression of its isoforms was not examined.
Methods: 30 GCTs (16 primaries, 14 relapses) were investigated immunohistochemically with
antibodies against Pan-CD56 (CD56Pan) and the isoform with 140/180 kDa length (CD56140/180 kDa).
The reaction was assessed with respect to percentage of positive cells and intensity of staining.
Results: In all GCTs, CD56Pan was expressed, but differences were found between primaries and
relapses. The percentage of CD56Pan positive tumor cells was lower in relapses, whereas CD56140/
180 kDa showed a higher staining intensity in the latter.
Conclusion: Expression of CD56 is an additional sensitive and helpful immunohistochemical tool
for histopathologists diagnosing a GCT. It does not seem possible to provide a validly individual risk
assessement. However, the different expression of CD56 isoforms might indicate important
changes in the course to a more malignant behaviour.
Background
Adult granulosa cell tumors (GCTs) of the ovary common
are sex cord stromal tumors of unpredictable clinical
behavior. They account for 2–5% of all ovarian neo-
plasms [1]. The reported 5-year survival is 75–90% in
FIGO stage I, 55–75 % in stage II, and 22–50 % in stages
III/IV [2,3]. An important problem for therapeutic deci-
sions apart from surgery is the unpredictable course of dis-
ease. Considerable efforts have been undertaken to
predict the risk of relapse or metastasizing. Correlations
between more malignant behavior and patients' age, men-
strual status, incomplete surgery, mitotic count, or prolif-
erative activity have been reported [3-6]. The influence of
mutated cell cycle regulatory proteins like p53 or other
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molecular changes remained unclear [7-11]. So far, relia-
ble parameters are not defined.
CD56 is expressed in adult neural, neuroectodermal, and
neuroendocrine tissue and different tumors [12] as neu-
roendocrine tumors, plasmocytomas, or melanomas. Its
expression identifies a subgroup of tumors with an unfa-
vorable prognosis e.g. in myeloid leukemia, adenoid
cystic carcinoma, squamous cell carcinoma, or renal cell
carcinoma [13-16].
CD56 is a membrane-bound cell surface sialoglycopro-
tein and a member of the immunoglobulin supergene
family which induce cell-to-cell interactions during
embryonic development, cell migration, and organogene-
sis [17-19]. Three main isoforms with molecular weights
of 120, 140, and 180 kDa are known. These are generated
from a single gene by alternative splicing. At least 20
major exons contribute for encoding these different iso-
forms, and further small exons can give rise additional iso-
forms [17]. The appearance of the 140/180 kDa isoform
was found to be associated with a higher degree of malig-
nancy [20].
In GCTs, only two studies are available which report an
expression of CD56 [21,22]. An analysis of its isoforms
was not performed up to now.
Methods
Specimen
30 primary and relapsed GCTs of 19 patients (surgery
between 1996 and 2007) were investigated. 16 GCTs were
primary tumors, 14 were relapses. Eleven relapses of 4
patients were available for direct comparison with the pri-
mary. Three further relapsed GCTs were initially diag-
nosed and treated loco alieno, unfortunately the
specimen of their primaries were not disposable for this
study. Medical records of all patients were available. The
follow up time ranged from 24 months to 16 years.
Staining
After surgical resection, the specimen were formalin fixed
and paraffin embedded. 2 μm sections of the routinely
processed paraffin blocks were stained with hematoxylin-
eosin (HE) for histopathological diagnosis. Only cases
with typical morphology were included. Proving the diag-
nosis, all cases were stained with vimentin (Mouse, V9,
1:400, DAKO) and inhibin (Mouse, R1, 1:40, Serotec)
and found positive.
Immunohistochemical stainings for CD56 were per-
formed in the usual immunoperoxidase technique (Kit:
Advance HRP, DAKO). Following antibodies against were
used: CD56Pan, which recognizes all isoforms (Mouse,
1BC, 1:40, Novocastra), and CD56140/180 kDa (Mouse,
NCAM-OB11, 1:500, Sigma). Additionally, Ki67 (MIB-1,
1:200, Dako) was stained. Only areas with antigen integ-
rity (vimentin+, inhibin+) were evaluated. The minimal
size of representative areas was 1.5 × 1.5 cm. One sample
per cm tumor diameter was investigated, the median val-
ues were gathered for calculation.
Analysis and Statistics
Immunohistochemical reactions with CD56 were dis-
criminated in a weak (1), moderate (2), or strong (3)
staining intensity. The intensity was assessed by compari-
son with a strong reaction in the positive controls (small
cell neuroendocrine carcinomas of the lung). The percent-
age of stained tumor cells was determined semiquantita-
tively.
All data were analyzed using Microsoft Office Excel® and
SPSS®. The descriptive statistical values, i.e. average,
median, minimum, maximum, and standard deviation/
standard error were computed. Furthermore, the signifi-
cance of differences was tested by Chi-Square test resp.
Mann-Whitney-U-test.
Results
Clinical data
Table 1 shows data of patients. 11 patients were premen-
opausal, 8 postmenopausal at time of first surgery. 12/19
Table 1: Clinical data at the time of first surgery
Primaries with relapse Primaries without relapse
during observation period
Age [years] 
(Average, Min, Max)
55.1 (23–78) 57.3 (34–85)
Menopausal at first
surgery
4 premenopausal
3 postmenopausal
7 premenopausal
5 postmenopausal
Tumor size [cm] 
(Average, Min, Max)
13.4 (2.5–26) 7.8 (4–25)
FIGO stage 5* FIGO I
2* FIGO II
8* FIGO I
4* FIGO IIDiagnostic Pathology 2008, 3:29 http://www.diagnosticpathology.org/content/3/1/29
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(63.2%) primaries were free of relapses over 36 months
up to 16 years. Relapses occurred 30 months up to 8 years
after initial diagnosis, no more than four relapses/patient
were found.
In the cases (primaries or relapses) investigated here, the
primary tumor stage was in 11 cases FIGO I (IA:7, IB:1,
IC:1) and in 6 cases FIGO II (IIA:4, IIB:2). In 2 cases, the
FIGO stage was not exactly documented, but the clinical
data correspond with FIGO I.
Between primary and relapsed GCTs, patients' age, first
tumor stage (mostly FIGO I), or size of primary did not
differ significantly.
Conventional parameters
The proliferation (Ki67) was 4.5% (1–10) in primaries
and 11.3% (2–40) in relapses (P < 0.05). Moreover, the
relapses harbored a significant higher number of cases
with a proliferation above 10% (3/16 vs. 6/12; P <
0.0001). However, the proliferation was not different
between primaries with and without relapse (4.0%, 1–5
vs. 4.6%, 1–10). The mitotic index per high power field
(HPF) did not differ significantly between primaries and
relapses (2.0/HPF, 0–10 vs. 3.3/HPF, 0–17) resp. between
the two groups of primaries (1.75/HPF, 1–3 vs. 2.0/HPF,
0–10).
Expression of CD56
All tumors, both primaries and relapses, stained positive
for CD56Pan. 9/16 primaries (56.3%) reacted with
CD56140/180 kDa, 8/14 relapses (57.1%) were positive. In
primaries, the median of positive cells for CD56Pan was
80% (5–100) and 5% (5–80) for CD56140/180 kDa (P <
0.05). Relapses showed a median of 35% (5–100) posi-
tive cells in CD56Pan and 5% (0–80) for CD56140/180 kDa (P
< 0.05). Figure 1 gives examples for staining, figure 2 indi-
cates these data in comparison of primaries without
Examples for CD56 staining (Immunoperoxidase ×400) Figure 1
Examples for CD56 staining (Immunoperoxidase ×400). A) Strong expression of CD56Pan in nearly all tumor cells in a unre-
lapsed case, B) Weak reaction with the same antibody in only few tumor cells of a relapse (4th relapse of another case), C) 
Expression of CD56140/180 kDa in a relapse, and D) Strong expression of the same in nearly all tumor cells of its primary.Diagnostic Pathology 2008, 3:29 http://www.diagnosticpathology.org/content/3/1/29
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relapse, primaries with relapse and the relapsed tumors.
The percentage of positive tumor cell classified in three
groups with >70%, >50%, and >30% positive cells
showed no significant differences (figure 3).
Positive cells in unrelapsed primaries showed a significant
lower staining intensity for CD56140/180 kDa compared
with CD56Pan. In relapses and their primaries, the stain-
ing intensity was higher than in unrelapsed primaries (fig-
ure 4).
CD56Pan was strongly expressed in 7/16 primaries and 10/
14 relapses, CD56140/180 kDa in 1/16 primaries and 4/14
relapses. The differences were not significant.
Discussion
The expression of CD56 (neural cell adhesion molecule,
NCAM) in adult granulosa cell tumor of the ovary (GCTs)
was previously described in two studies [21,22]. The
expression of CD56Pan and the isoform CD56140/180 kDa
was not investigated up to now.
We investigated 16 primaries and 14 relapses (of together
7 primaries). The number is not high enough for compre-
hensive statistical evaluation, but seems adequately for
insights in expression profiles for CD56 in these rare
tumors.
GCTs express CD56 constantly. This finding constitutes a
further diagnostic tool for the surgical pathologist apart
from inhibin or vimentin. In difficult cases, the differen-
tial diagnosis of GCT may be provided by positivity of
CD56 in discrimination e.g. of poorly differentiated carci-
noma or endometrial stromal sarcoma [21]. However,
expression of CD56 alone can not prove a GCT because of
the possibility of positive reaction in a lot of other malig-
nant tumors [12-16].
Human granulosa cells of pre-ovulatory follicles and the-
cal cells have been detected to express CD56 [17,22]. Sim-
ilar to inhibin or activin, CD56 is a regulator of growth
and differentiation in ovarian folliculogenesis [23]. Thus,
it is understandable that GCTs express CD56. It seems to
be an important factor involved in the recognition and
intercellular interaction of ovarian endocrine cells and
participates in the regulation of the cyclic remodeling
processes of the ovarian endocrine compartments [18].
The major function of CD56 is the homophilic binding
NCAM-NCAM [16]. In clusters of granulosa cells of folli-
cles, CD56 was found by Mayerhofer et al., whereas cells
devoiding CD56 spread out and form monolayers [18].
CD56 is thought to favor the development of metastases
by supporting cell dissociation processes [16,24,25]. We
found a less number of tumor cells positive for CD56Pan
Percentage of positive stained tumor cells (average with standard error, bar: median) Figure 2
Percentage of positive stained tumor cells (average with standard error, bar: median).
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Number of cases distributed in three groups (>70%, >50%, >30% positive cells) Figure 3
Number of cases distributed in three groups (>70%, >50%, >30% positive cells). No significant differences between primaries 
with and without relapse and relapses.
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in primaries with relapse and relapsed GCTs (not signifi-
cant, but clear trend). Loss of CD56 could be interpreted
as a sign of dedifferentiation during the tumor progres-
sion and with respect to the binding function of CD56 to
a loosening of cell adhesion. Differences in the percentage
of positive tumor cells in GCTs were also reported by Ohi-
shi et al., but not analyzed in this matter [21].
In several malignant tumors, CD56 expression predicts a
more aggressive biological behavior [13,14,16,24,26,27],
especially in presence of the 140/180 kDa isoform [20]. In
GCTs, we found a more frequent appearance of strong
expression of CD56140/180 kDa in relapsing primaries and
relapses in comparison to unrelapsed primaries. This shift
to the high molecular isoform could be interpreted as a
hint for the more aggressive biological behavior of relaps-
ing cases. However, the findings of expression in this
small cohort seem sufficient for refusing a predictive value
of CD56 expression, because of the heterogenous distri-
bution.
Increased mitotic count and proliferation were associated
with relapsing as reported before [2,28,29]. However,
these markers are also not suitable for prediction of
behaviour, because we found only differences between
primaries and relapses, but not between relapsing and
unrelapsed primaries. Another conventional factors
reported associated with a good prognosis are low FIGO
stage, small tumor size (<10–15 cm), and unruptured
tumor during surgery [2]. However, even though FIGO
stage is thought as an important criterion, the tumor stage
does not give valid information regarding the prognosis,
since the majority of GCTs is diagnosed at stage I [2].
Conclusion
CD56 is constantly expressed in adult granulosa cell
tumors of ovary. Its expression is most probably deter-
mined by tumor histogenesis. Therefore, apart from other
immunohistochemical markers like inhibin, the detection
of CD56 in GCTs is a helpful diagnostic tool for the his-
topathologist in difficult cases. However, an individual
prediction of clinical behavior via expression of CD56 iso-
forms is not possible.
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